Summary by Futu AI
On April 15, 2024, Novo Integrated Sciences, Inc. (Novo), a healthcare company listed on the Nasdaq Capital Market under the symbol NVOS, released its financial results for the second fiscal quarter ending February 29, 2024. The company, headquartered in Bellevue, Washington, reported a 24% increase in revenues to $3,170,592 compared to the same period in the previous year, primarily due to an increase in product sales. Despite the revenue growth, Novo experienced a net loss of $2,746,128 for the quarter, which is a 41% improvement from the $4,621,355 loss reported for the quarter ending February 28, 2023. The reduction in net loss is attributed to an increase in gross profit and a decrease in other expenses. Novo also highlighted the conversion of a promissory note into common stock, which settled the...Show More